Merck
Search Within

I8657

Applied Filters:
Keyword:'I8657'
Showing 1-10 of 10 results for "I8657" within Papers
Masaya Sugiyama et al.
PloS one, 6(10), e26620-e26620 (2011-11-03)
The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-α (PEG-IFNα) and ribavirin (RBV). The treatment achieves a sustained viral clearance in only approximately 50% of patients. Recent whole genome association studies revealed that single
S Rubinstein et al.
Journal of virology, 37(2), 755-758 (1981-02-01)
A convenient assay for interferons based on reduction of cytopathic effect was developed. The number of manipulations and the lengths of the various incubation steps were reduced to a minimum. The assay is simple to perform and can be completed
Interferon standards and general abbreviations.
S Pestka
Methods in enzymology, 119, 14-23 (1986-01-01)
A convenient and rapid cytopathic effect inhibition assay for interferon.
P C Familletti et al.
Methods in enzymology, 78(Pt A), 387-394 (1981-01-01)
Interferon- ? therapy in bcr-abl-negative myeloproliferative neoplasms
Kiladjian JJ, et al.
Leukemia, 22(11), 1990-1990 (2008)
Jin Zhao et al.
PloS one, 8(5), e64301-e64301 (2013-06-07)
The cytokine interleukin-28B (IL-28B) has potential antiviral properties and regulatory roles in adaptive cellular immunity. A genome-wide association study identified a single nucleotide polymorphism near the IL-28B gene that strongly predicts response to hepatitis C treatment with interferon and ribavirin.
Agnieszka Rynda et al.
PloS one, 5(1), e8720-e8720 (2010-01-22)
Conventional methods to induce tolerance in humans have met with limited success. Hence, efforts to redirect tolerogen uptake using reovirus adhesin, protein sigma 1 (psigma1), may circumvent these shortcomings based upon the recent finding that when reovirus psigma1 is engineered
The interferon system of teleost fish
Robertsen B
Fish & Shellfish Immunology, 20(2), 172-191 (2006)
Type I interferons (?/?) in immunity and autoimmunity
Theofilopoulos AN, et al.
Fish & Shellfish Immunology, 23(11), 307-335 (2005)
Jie-Hyun Kim et al.
Yonsei medical journal, 47(6), 793-798 (2006-12-28)
Combination therapy with interferon alpha (IFN-alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy
Page 1 of 1